Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial
If successful, new clinical study expected to supp.
/PRNewswire/ This past Saturday, April 29, the Pancreatic Cancer Action Network (PanCAN) held its largest annual fundraiser, PanCAN PurpleStride®, the.
/PRNewswire/ The Pancreatic Cancer Action Network (PanCAN) received a $25 million gift that will accelerate the organization s critical research initiatives.
Cancer deaths continue to decline, dropping 33% since 1991 and saving an estimated 3.8 million lives, according to the American Cancer Society's annual statistics report.
The five-year survival rate for pancreatic cancer has reached an all-time high of 12%, the American Cancer Society announced Thursday, marking the first time since 2017 the rate has increased two consecutive years.